The table below shows Vaxcyte, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$280.63M
-$166.27M
-$159.12M
-$47.69M
-$27.70M
-$13.21M
Capital expenditure
$2.11M
$5.42M
$5.68M
$5.61M
$2.92M
$1.25M
Investing cash flow
-$233.41M
$123.32M
-$451.07M
-$448.10M
$49.67M
-$173.39M
Dividends paid
-
-
-
PCVX operating cash flow (10-K history)
Vaxcyte, Inc. reported operating cash flow of -$655.58M for fiscal year 2025. That is down 44.8% from -$452.63M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$30.47M (FY 2018) to -$655.58M. Figures come from the company's audited annual reports as filed with the SEC.